ID   MAPK5_HUMAN             Reviewed;         473 AA.
AC   Q8IW41; B3KVA5; O60491; Q86X46; Q9BVX9; Q9UG86;
DT   13-SEP-2004, integrated into UniProtKB/Swiss-Prot.
DT   13-SEP-2004, sequence version 2.
DT   15-MAR-2017, entry version 148.
DE   RecName: Full=MAP kinase-activated protein kinase 5;
DE            Short=MAPK-activated protein kinase 5;
DE            Short=MAPKAP kinase 5;
DE            Short=MAPKAP-K5;
DE            Short=MAPKAPK-5;
DE            Short=MK-5;
DE            Short=MK5;
DE            EC=2.7.11.1;
DE   AltName: Full=p38-regulated/activated protein kinase;
DE            Short=PRAK;
GN   Name=MAPKAPK5; Synonyms=PRAK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2), MUTAGENESIS OF THR-182,
RP   FUNCTION, TISSUE SPECIFICITY, PHOSPHORYLATION AT THR-182, AND ENZYME
RP   REGULATION.
RC   TISSUE=Placenta;
RX   PubMed=9628874; DOI=10.1093/emboj/17.12.3372;
RA   New L., Jiang Y., Zhao M., Liu K., Zhu W., Flood L.J., Kato Y.,
RA   Parry G.C.N., Han J.;
RT   "PRAK, a novel protein kinase regulated by the p38 MAP kinase.";
RL   EMBO J. 17:3372-3384(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Cervix, Pancreas, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 133-473 (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   INTERACTION WITH SQSTM1, ENZYME REGULATION, AND SUBCELLULAR LOCATION.
RX   PubMed=10708586; DOI=10.1006/bbrc.2000.2333;
RA   Sudo T., Maruyama M., Osada H.;
RT   "p62 functions as a p38 MAP kinase regulator.";
RL   Biochem. Biophys. Res. Commun. 269:521-525(2000).
RN   [7]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-212, MUTAGENESIS OF
RP   THR-182, AND MUTAGENESIS OF LYS-51; THR-182 AND SER-212.
RX   PubMed=12808055; DOI=10.1091/mbc.E02-08-0538;
RA   New L., Jiang Y., Han J.;
RT   "Regulation of PRAK subcellular location by p38 MAP kinases.";
RL   Mol. Biol. Cell 14:2603-2616(2003).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF HSPB1, AND INTERACTION WITH YWHAE.
RX   PubMed=17728103; DOI=10.1016/j.cellsig.2007.07.016;
RA   Tak H., Jang E., Kim S.B., Park J., Suk J., Yoon Y.S., Ahn J.K.,
RA   Lee J.H., Joe C.O.;
RT   "14-3-3epsilon inhibits MK5-mediated cell migration by disrupting F-
RT   actin polymerization.";
RL   Cell. Signal. 19:2379-2387(2007).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF HSPB1.
RX   PubMed=19166925; DOI=10.1016/j.cellsig.2009.01.009;
RA   Kostenko S., Johannessen M., Moens U.;
RT   "PKA-induced F-actin rearrangement requires phosphorylation of Hsp27
RT   by the MAPKAP kinase MK5.";
RL   Cell. Signal. 21:712-718(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-182, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-182 AND SER-354, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-67 AND LYS-282.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF TP53.
RX   PubMed=17254968; DOI=10.1016/j.cell.2006.11.050;
RA   Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C.,
RA   Chen J., Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R. III,
RA   Wright P.E., Han J.;
RT   "PRAK is essential for ras-induced senescence and tumor suppression.";
RL   Cell 128:295-308(2007).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF FOXO3, AUTOPHOSPHORYLATION, INDUCTION,
RP   AND MUTAGENESIS OF THR-182 AND LEU-337.
RX   PubMed=21329882; DOI=10.1016/j.molcel.2011.01.023;
RA   Kress T.R., Cannell I.G., Brenkman A.B., Samans B., Gaestel M.,
RA   Roepman P., Burgering B.M., Bushell M., Rosenwald A., Eilers M.;
RT   "The MK5/PRAK kinase and Myc form a negative feedback loop that is
RT   disrupted during colorectal tumorigenesis.";
RL   Mol. Cell 41:445-457(2011).
RN   [17]
RP   REVIEW.
RX   PubMed=20227494; DOI=10.1016/j.cellsig.2010.03.002;
RA   Shiryaev A., Moens U.;
RT   "Mitogen-activated protein kinase p38 and MK2, MK3 and MK5: menage a
RT   trois or menage a quatre?";
RL   Cell. Signal. 22:1185-1192(2010).
CC   -!- FUNCTION: Tumor suppressor serine/threonine-protein kinase
CC       involved in mTORC1 signaling and post-transcriptional regulation.
CC       Phosphorylates FOXO3, ERK3/MAPK6, ERK4/MAPK4, HSP27/HSPB1,
CC       p53/TP53 and RHEB. Acts as a tumor suppressor by mediating Ras-
CC       induced senescence and phosphorylating p53/TP53. Involved in post-
CC       transcriptional regulation of MYC by mediating phosphorylation of
CC       FOXO3: phosphorylation of FOXO3 leads to promote nuclear
CC       localization of FOXO3, enabling expression of miR-34b and miR-34c,
CC       2 post-transcriptional regulators of MYC that bind to the 3'UTR of
CC       MYC transcript and prevent MYC translation. Acts as a negative
CC       regulator of mTORC1 signaling by mediating phosphorylation and
CC       inhibition of RHEB. Part of the atypical MAPK signaling via its
CC       interaction with ERK3/MAPK6 or ERK4/MAPK4: the precise role of the
CC       complex formed with ERK3/MAPK6 or ERK4/MAPK4 is still unclear, but
CC       the complex follows a complex set of phosphorylation events: upon
CC       interaction with atypical MAPK (ERK3/MAPK6 or ERK4/MAPK4),
CC       ERK3/MAPK6 (or ERK4/MAPK4) is phosphorylated and then mediates
CC       phosphorylation and activation of MAPKAPK5, which in turn
CC       phosphorylates ERK3/MAPK6 (or ERK4/MAPK4). Mediates
CC       phosphorylation of HSP27/HSPB1 in response to PKA/PRKACA
CC       stimulation, inducing F-actin rearrangement.
CC       {ECO:0000269|PubMed:17254968, ECO:0000269|PubMed:17728103,
CC       ECO:0000269|PubMed:19166925, ECO:0000269|PubMed:21329882,
CC       ECO:0000269|PubMed:9628874}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Activated following phosphorylation at Thr-182
CC       by p38-alpha/MAPK14, p38-beta/MAPK11, ERK2/MAPK1, ERK3/MAPK6, and
CC       ERK4/MAPK4. Activated by stress-related extracellular stimuli;
CC       such as H(2)O(2), arsenite, anisomycin TNF alpha and also PMA and
CC       the calcium ionophore A23187; but to a lesser extent. In vitro,
CC       activated by SQSTM1. Inhibited by diterpenoid alkaloid
CC       noroxoaconitine. {ECO:0000269|PubMed:10708586,
CC       ECO:0000269|PubMed:9628874}.
CC   -!- SUBUNIT: Interacts with ERK3/MAPK6 and ERK4/MAPK4 (via FRIEDE
CC       motif); the interaction is direct (By similarity). Interacts with
CC       YWHAE; the interaction prevents phosphorylation of HSP27/HSPB1
CC       leading to disrupt F-actin polymerization. Interacts with SQSTM1.
CC       {ECO:0000250, ECO:0000269|PubMed:10708586,
CC       ECO:0000269|PubMed:17728103}.
CC   -!- INTERACTION:
CC       P04792:HSPB1; NbExp=2; IntAct=EBI-1201460, EBI-352682;
CC       Q16659:MAPK6; NbExp=7; IntAct=EBI-1201460, EBI-1384105;
CC       P04637:TP53; NbExp=2; IntAct=EBI-1201460, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Translocates to the
CC       cytoplasm following phosphorylation and activation. Interaction
CC       with ERK3/MAPK6 or ERK4/MAPK4 and phosphorylation at Thr-182,
CC       activates the protein kinase activity, followed by translocation
CC       to the cytoplasm. Phosphorylation by PKA/PRKACA at Ser-115 also
CC       induces nuclear export.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8IW41-1; Sequence=Displayed;
CC         Note=No experimental confirmation available.;
CC       Name=2;
CC         IsoId=Q8IW41-2; Sequence=VSP_011597;
CC   -!- TISSUE SPECIFICITY: Expressed ubiquitously.
CC       {ECO:0000269|PubMed:9628874}.
CC   -!- INDUCTION: Directly regulated by MYC: expression is activated by
CC       MYC, suggesting the existence of a feedback regulatory loop.
CC       {ECO:0000269|PubMed:21329882}.
CC   -!- PTM: Phosphorylated on Thr-182 ERK3/MAPK6 or ERK4/MAPK4; which is
CC       the regulatory phosphorylation site and is located on the T-
CC       loop/loop 12, leading to activation. Phosphorylation at Thr-182 by
CC       p38-alpha/MAPK14, p38-beta/MAPK11 is subject to debate.
CC       Phosphorylated at Ser-115 by PKA/PRKACA, leading to localization
CC       to the cytoplasm. Autophosphorylated (By similarity).
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. {ECO:0000305}.
CC   -!- CAUTION: The role of p38 MAPK kinases is unclear in
CC       phosphorylation and activation of MAPKAPK5. According to some
CC       reports, it interacts and is phosphorylated by p38-alpha/MAPK14
CC       and p38-beta/MAPK11 (PubMed:9628874 and PubMed:12808055).
CC       According to other reports, it is not activated by p38-
CC       alpha/MAPK14 and p38-beta/MAPK11. An explanation for these
CC       discrepancies, might be that the interaction with p38 MAPK kinases
CC       is weak and occurs only under specific conditions. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF032437; AAC39863.1; -; Genomic_DNA.
DR   EMBL; AK122767; BAG53717.1; -; mRNA.
DR   EMBL; CH471054; EAW97981.1; -; Genomic_DNA.
DR   EMBL; BC000833; AAH00833.1; -; mRNA.
DR   EMBL; BC041049; AAH41049.1; -; mRNA.
DR   EMBL; BC047284; AAH47284.2; -; mRNA.
DR   EMBL; AL110301; CAB53747.1; -; mRNA.
DR   CCDS; CCDS44975.1; -. [Q8IW41-1]
DR   CCDS; CCDS44976.1; -. [Q8IW41-2]
DR   PIR; T34519; T34519.
DR   RefSeq; NP_003659.2; NM_003668.3. [Q8IW41-2]
DR   RefSeq; NP_620777.1; NM_139078.2. [Q8IW41-1]
DR   UniGene; Hs.333120; -.
DR   UniGene; Hs.413901; -.
DR   ProteinModelPortal; Q8IW41; -.
DR   SMR; Q8IW41; -.
DR   BioGrid; 114120; 20.
DR   IntAct; Q8IW41; 18.
DR   MINT; MINT-4711647; -.
DR   STRING; 9606.ENSP00000202788; -.
DR   BindingDB; Q8IW41; -.
DR   ChEMBL; CHEMBL3094; -.
DR   GuidetoPHARMACOLOGY; 2096; -.
DR   iPTMnet; Q8IW41; -.
DR   PhosphoSitePlus; Q8IW41; -.
DR   DMDM; 52000829; -.
DR   MaxQB; Q8IW41; -.
DR   PaxDb; Q8IW41; -.
DR   PeptideAtlas; Q8IW41; -.
DR   PRIDE; Q8IW41; -.
DR   DNASU; 8550; -.
DR   Ensembl; ENST00000550735; ENSP00000449667; ENSG00000089022. [Q8IW41-2]
DR   Ensembl; ENST00000551404; ENSP00000449381; ENSG00000089022. [Q8IW41-1]
DR   GeneID; 8550; -.
DR   KEGG; hsa:8550; -.
DR   UCSC; uc001tta.5; human. [Q8IW41-1]
DR   CTD; 8550; -.
DR   DisGeNET; 8550; -.
DR   GeneCards; MAPKAPK5; -.
DR   HGNC; HGNC:6889; MAPKAPK5.
DR   HPA; CAB004546; -.
DR   HPA; HPA015515; -.
DR   MIM; 606723; gene.
DR   neXtProt; NX_Q8IW41; -.
DR   OpenTargets; ENSG00000089022; -.
DR   PharmGKB; PA30633; -.
DR   eggNOG; KOG0604; Eukaryota.
DR   eggNOG; ENOG410XP8F; LUCA.
DR   GeneTree; ENSGT00830000128274; -.
DR   HOGENOM; HOG000233031; -.
DR   HOVERGEN; HBG106948; -.
DR   InParanoid; Q8IW41; -.
DR   KO; K04442; -.
DR   OMA; IHDRENG; -.
DR   OrthoDB; EOG091G14PL; -.
DR   PhylomeDB; Q8IW41; -.
DR   TreeFam; TF312891; -.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-5687128; MAPK6/MAPK4 signaling.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   SignaLink; Q8IW41; -.
DR   SIGNOR; Q8IW41; -.
DR   ChiTaRS; MAPKAPK5; human.
DR   GeneWiki; MAPKAPK5; -.
DR   GenomeRNAi; 8550; -.
DR   PRO; PR:Q8IW41; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000089022; -.
DR   CleanEx; HS_MAPKAPK5; -.
DR   ExpressionAtlas; Q8IW41; baseline and differential.
DR   Genevisible; Q8IW41; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0009931; F:calcium-dependent protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0005516; F:calmodulin binding; IBA:GO_Central.
DR   GO; GO:0004683; F:calmodulin-dependent protein kinase activity; IBA:GO_Central.
DR   GO; GO:0004708; F:MAP kinase kinase activity; TAS:ProtInc.
DR   GO; GO:0002039; F:p53 binding; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0032007; P:negative regulation of TOR signaling; ISS:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0051973; P:positive regulation of telomerase activity; IMP:BHF-UCL.
DR   GO; GO:1904355; P:positive regulation of telomere capping; IMP:BHF-UCL.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; IDA:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0006417; P:regulation of translation; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0090400; P:stress-induced premature senescence; IDA:UniProtKB.
DR   Gene3D; 4.10.1170.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR027442; MAPKAPK_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Coiled coil; Complete proteome;
KW   Cytoplasm; Kinase; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase; Tumor suppressor.
FT   CHAIN         1    473       MAP kinase-activated protein kinase 5.
FT                                /FTId=PRO_0000086296.
FT   DOMAIN       22    304       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      28     36       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COILED      409    440       {ECO:0000255}.
FT   ACT_SITE    148    148       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      51     51       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     115    115       Phosphoserine; by PKA. {ECO:0000250}.
FT   MOD_RES     182    182       Phosphothreonine; by MAPK11, MAPK14,
FT                                MAPK4, MAPK6 and PKA.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:9628874}.
FT   MOD_RES     212    212       Phosphoserine.
FT                                {ECO:0000269|PubMed:12808055}.
FT   MOD_RES     354    354       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     407    408       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_011597.
FT   VARIANT      67     67       M -> I (in dbSNP:rs34132040).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040758.
FT   VARIANT     282    282       R -> K (in dbSNP:rs34843470).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040759.
FT   MUTAGEN      51     51       K->M: Kinase defective mutant, abolishes
FT                                activity. {ECO:0000269|PubMed:12808055}.
FT   MUTAGEN     182    182       T->A: No p38-beta/MAPK11-induced
FT                                activation. {ECO:0000269|PubMed:12808055,
FT                                ECO:0000269|PubMed:21329882,
FT                                ECO:0000269|PubMed:9628874}.
FT   MUTAGEN     182    182       T->D: Mimicks phosphorylation state and
FT                                induces constitutive protein kinase
FT                                activity. {ECO:0000269|PubMed:12808055,
FT                                ECO:0000269|PubMed:21329882,
FT                                ECO:0000269|PubMed:9628874}.
FT   MUTAGEN     212    212       S->D: Mimicks phosphorylation state and
FT                                displays a slightly higher protein kinase
FT                                activity. {ECO:0000269|PubMed:12808055}.
FT   MUTAGEN     337    337       L->G: Induces constitutive protein kinase
FT                                activity. {ECO:0000269|PubMed:21329882}.
FT   CONFLICT    273    273       I -> T (in Ref. 5; CAB53747).
FT                                {ECO:0000305}.
FT   CONFLICT    291    291       E -> R (in Ref. 1; AAC39863).
FT                                {ECO:0000305}.
SQ   SEQUENCE   473 AA;  54220 MW;  F3D9DDC83CC0C49D CRC64;
     MSEESDMDKA IKETSILEEY SINWTQKLGA GISGPVRVCV KKSTQERFAL KILLDRPKAR
     NEVRLHMMCA THPNIVQIIE VFANSVQFPH ESSPRARLLI VMEMMEGGEL FHRISQHRHF
     TEKQASQVTK QIALALRHCH LLNIAHRDLK PENLLFKDNS LDAPVKLCDF GFAKIDQGDL
     MTPQFTPYYV APQVLEAQRR HQKEKSGIIP TSPTPYTYNK SCDLWSLGVI IYVMLCGYPP
     FYSKHHSRTI PKDMRRKIMT GSFEFPEEEW SQISEMAKDV VRKLLKVKPE ERLTIEGVLD
     HPWLNSTEAL DNVLPSAQLM MDKAVVAGIQ QAHAEQLANM RIQDLKVSLK PLHSVNNPIL
     RKRKLLGTKP KDSVYIHDHE NGAEDSNVAL EKLRDVIAQC ILPQAGKGEN EDEKLNEVMQ
     EAWKYNRECK LLRDTLQSFS WNGRGFTDKV DRLKLAEIVK QVIEEQTTSH ESQ
//
